IMMUNOTHERAPY WITH A POLYVALENT MELANOMA VACCINE PLUS BCG IN STAGE IV

IV 期多价黑色素瘤疫苗加卡介苗的免疫治疗

• 批准号: 7377398
• 负责人: DAVID W OLLILA
• 金额: $ 0.2万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377398
• 关键词: IMMUNOTHERAPY; POLYVALENT; MELANOMA; VACCINE; PLUS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to determine whether Bacillus Calmette Guerin (BCG), a bovine tubercle germ in combination with melanoma vaccine (C-VAX) is more effective than BCG and a placebo in stimulation of an immune response against melanoma, in improving overall survival, and increasing a delay in recurrence following surgery. This research is being done because there is no currently approved treatment of melanoma, which prolongs the time to recurrence. It is hoped that C-VAX, an experimental vaccine, will have benefits, which will help alleviate this problem.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究旨在确定卡介苗(BCG)与黑色素瘤疫苗(C-VAX)联合使用是否比卡介苗和安慰剂更有效地刺激对黑色素瘤的免疫反应，提高总体存活率，并增加手术后复发的延迟。之所以进行这项研究，是因为目前还没有被批准的治疗黑色素瘤的方法，这会延长复发的时间。希望C-VAX这一实验性疫苗会有好处，这将有助于缓解这一问题。